A phase III trial to combine the effects of a group of medications with another combination in patients with newly diagnosed Symptomatic Multiple Myeloma
This randomized phase III trial studies lenalidomide, dexamethasone, and bortezomib to see how well it works compared to dexamethasone and lenalidomide alone in treating patients with previously untreated multiple myeloma. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth or by blocking blood flow to the cancer. It is not yet known whether lenalidomide and dexamethasone is more effective with or without bortezomib in treating multiple myeloma.
This research study is led by Dr. Syed Ali.
Contact: Katie Colbeck, 413-794-9875
April 01, 2008
Cancer - Leukemia,
D’Amour Center for Cancer Care, 3350 Main Street, Springfield, MA
Newly diagnosed multiple myeloma
Interventional (Clinical Trial), Randomized